5349-17-7

Basic information

• Product Name: 4-(Bromoacetyl)pyridine hydrobromide
• Synonyms: BUTTPARK 37\12-45;2-BROMO-1-PYRDIN-4-YLETHAN-1-ONE HYDROBROMIDE;2-BROMO-1-(4-PYRIDINYL)-1-ETHANONE HYDROBROMIDE;4-(BROMOACETYL)PYRIDINE HYDROBROMIDE;4-(2-BROMO-ACETYL)-PYRIDINIUM, BROMIDE;2-Bromo-1-pyridin-4-ylethanone hydrobromide;2-Bromo-1-pyrdin-3-ylethan-1-one hydrobromide;2-Bromo-1-(pyridin-4-yl)ethan-1-one hydrobromide
• CAS NO: 5349-17-7
• Molecular Formula: BrH*C₇H₆BrNO
• Molecular Weight: 280.94
• EINECS: 1806241-263-5
• Product Categories: Acetyl Halides;Pyridines;Heterocyclic Compounds;CHIRAL CHEMICALS;Acetyl Halides
• Mol File: 5349-17-7.mol
• Article Data: 30

Chemical Properties

• Melting Point: 194 °C
• Boiling Point: 324.9 °C at 760 mmHg
• Flash Point: 150.3 °C
• Appearance: /
• Density: 1.57g/cm3
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Water Solubility: Soluble in water.
• CAS DataBase Reference: 4-(Bromoacetyl)pyridine hydrobromide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Bromoacetyl)pyridine hydrobromide(5349-17-7)
• EPA Substance Registry System: 4-(Bromoacetyl)pyridine hydrobromide(5349-17-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39-37/39
• HazardClass: 8
• Hazardous Substances Data: 5349-17-7(Hazardous Substances Data)

Usage

Uses

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase 4-(Bromoacetyl)pyridine hydrobromide was used to prepare 2-Phenyl-4-(4-pyridyl)imidazole.

InChI:InChI=1/C7H6BrNO.BrH/c8-5-7(10)6-1-3-9-4-2-6;/h1-4H,5H2;1H

Upstream product

• 350-03-8 methyl-3-pyridylketone 
• 1122-54-9 methyl (4-pyridyl) ketone 

Downstream Products

• 234766-97-3 4-(2-phenyl-1H-imidazol-5-yl)pyridine 
• 216970-85-3 4-(N-benzyl-N-methylaminoacetyl)pyridine 
• 929561-61-5 C₂₁H₂₃ClN₄O₂S 
• 929561-62-6 C₂₁H₂₃ClN₄O₃S 
• 929562-42-5 C₁₇H₁₆ClN₃O₃S 
• 1203709-45-8 C₁₇H₁₅Cl₂N₃O₂S 
• 1400221-19-3 4-fluoro-3-(2-methyl-4-(pyridin-4-yl)thiazol-5-yl)aniline 
• 1400215-10-2 1-(3-(2-amino-4-(pyridin-4-yl)thiazol-5-yl)-2-fluorophenyl)-3-(4-(trifluoromethyl)phenyl)urea 
• 1400214-11-0 1-(3-(2-methyl-4-(pyridin-4-yl)thiazol-5-yl)phenyl)-3-p-tolylurea 
• 1400215-16-8 2,5-difluoro-N-(3-(2-methyl-4-(pyridin-4-yl)thiazol-5-yl)phenyl)benzenesulfonamide 
• 1400214-14-3 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(2-methyl-4-(pyridin-4-yl)thiazol-5-yl)phenyl)urea 
• 1400220-18-9 3-(2-methyl-4-pyridin-4-yl-thiazol-5-yl)-phenylamine 
• 1400220-23-6 3-(2-methyl-4-pyridin-4-yl-thiazol-5-yl)-phenylacetic acid 
• 892119-40-3 N-(2-methyl-5-nitrophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-amine 

Relevant articles and documents

SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof,wherein the ring containing Q1to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.

Preparation method of 4-(bromoacetyl) pyridine hydrobromide

The invention relates to the technical field of synthesis of medical intermediates, in particular to a preparation method of 4-(bromoacetyl) pyridine hydrobromide of a ceftaroline fosamil intermediate. The method comprises the following steps that 4-acetyl pyridine is used as a raw material, ester is used as a solvent and NBS serves as a bromination reagent to obtain the 4-(bromoacetyl) pyridine hydrobromide through reaction. The preparation method is mild in reaction condition, high in yield, high in safety, green, environmentally friendly, low in cost and suitable for industrial production.